Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants

Vaccine hesitancy and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) escaping vaccine-induced immune responses highlight the urgency for new COVID-19 therapeutics. Engineered angiotensin-converting enzyme 2 (ACE2) proteins with augmented binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lianghui, Dutta, Soumajit, Xiong, Shiqin, Chan, Matthew, Chan, Kui K., Fan, Timothy M., Bailey, Keith L., Lindeblad, Matthew, Cooper, Laura M., Rong, Lijun, Gugliuzza, Anthony F., Shukla, Diwakar, Procko, Erik, Rehman, Jalees, Malik, Asrar B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885411/
https://www.ncbi.nlm.nih.gov/pubmed/35046611
http://dx.doi.org/10.1038/s41589-021-00965-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885411/
https://www.ncbi.nlm.nih.gov/pubmed/35046611
http://dx.doi.org/10.1038/s41589-021-00965-6

Ejemplares similares